Posts
Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedOn the 2nd of May 2 2019, the FDA approved ivosidenib (Tibsovo®, Agios) as treatment for newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old and AML patients with comorbidities precluding intensive induction chemotherapy. Patients should harbour a susceptible IDH1 mutation, as per the FDA-approved Abbott RealTime™ IDH1 Assay, to be legible for ivosidenib treatment.
Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients
/0 Comments/in Haematology, Oncology, Paediatric, US FDA Onc\Haem Approvals /by News FeedOn 20 December 2018, the FDA approved the asparagine specific enzyme calaspargase pegol-mknl (Asparlas®, Servier) as a component of multi-agent chemotherapeutic regimens for the treatment of paediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukaemia (ALL).
Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedVenetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
/0 Comments/in Chemotherapy, Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedOn 21 November 2018, the FDA granted accelerated approval to venetoclax (Venclexta®, AbbVie/Genentech) in combination with either azacitidine, or decitabine, or low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old or in patients with comorbidities precluding intensive induction chemotherapy.
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
/0 Comments/in Chemotherapy, Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedOn 21 November 2018, the FDA approved glasdegib (Daurismo®, Pfizer) in combination with low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) in patients of 75 years or older and in patients with comorbidities contraindicating intensive induction chemotherapy.
Duvelisib FDA approved for adult patients with R/R CLL or SLL
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedMoxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedVenetoclax FDA label updated to include Minimal Residual Disease negativity data
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedOn the 11th of September 2018, the FDA updated the label of venetoclax tablets (VENCLEXTA®, Abbvie) in combination with rituximab (MabThera®, Roche) to include information about pre-treated patients with chronic lymphocytic leukemia (CLL) in the Phase III MURANO trial who had achieved Minimal Residual Disease (MRD)-negativity.
Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
/0 Comments/in Haematology, Medical News Asia, Oncology, Targeted Therapies /by News FeedTOKYO and MUNICH and BASKING RIDGE, N.J., September 11, 2018 — The Japan Ministry of Health, Labour and Welfare (MHLW) has granted quizartinib (AC220, Daiichi Sankyo), an investigational inhibitor of FLT3, the Orphan Drug designation for the treatment of acute myeloid leukaemia (AML) harbouring FLT3-mutations.
Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
/0 Comments/in Haematology, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by News FeedOn July 20, 2018, the US FDA approved ivosidenib (Tibsovo©, Agios Pharmaceuticals) for use in adult patients with relapsed or refractory acute myeloid leukaemia (AML) harbouring a susceptible IDH1 mutation as detected by an FDA-approved companion diagnostic (CDx) test, the Abbott RealTime IDH1 Assay.
FDA approves venetoclax in 2nd-line for patients with CLL or SLL
/0 Comments/in Haematology, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed
- FDA granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%
/0 Comments/in Haematology, ImmunoOncology, Immunotherapy, US FDA Onc\Haem Approvals /by News Feed
- FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and paediatric patients with B-cell precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. More Information.
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI
/0 Comments/in US FDA Onc\Haem Approvals /by News Feed
- FDA approved nilotinib (TASIGNA, Novartis Pharmaceuticals Corporation) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML–CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. More Information. March 22, 2018